全文获取类型
收费全文 | 4484篇 |
免费 | 229篇 |
国内免费 | 21篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 105篇 |
妇产科学 | 114篇 |
基础医学 | 409篇 |
口腔科学 | 109篇 |
临床医学 | 388篇 |
内科学 | 1122篇 |
皮肤病学 | 46篇 |
神经病学 | 166篇 |
特种医学 | 212篇 |
外国民族医学 | 1篇 |
外科学 | 791篇 |
综合类 | 125篇 |
一般理论 | 3篇 |
预防医学 | 279篇 |
眼科学 | 131篇 |
药学 | 347篇 |
中国医学 | 13篇 |
肿瘤学 | 349篇 |
出版年
2023年 | 47篇 |
2022年 | 139篇 |
2021年 | 233篇 |
2020年 | 98篇 |
2019年 | 133篇 |
2018年 | 176篇 |
2017年 | 93篇 |
2016年 | 92篇 |
2015年 | 126篇 |
2014年 | 163篇 |
2013年 | 196篇 |
2012年 | 301篇 |
2011年 | 294篇 |
2010年 | 194篇 |
2009年 | 157篇 |
2008年 | 252篇 |
2007年 | 256篇 |
2006年 | 236篇 |
2005年 | 233篇 |
2004年 | 160篇 |
2003年 | 160篇 |
2002年 | 151篇 |
2001年 | 62篇 |
2000年 | 76篇 |
1999年 | 55篇 |
1998年 | 38篇 |
1997年 | 27篇 |
1996年 | 25篇 |
1995年 | 21篇 |
1994年 | 27篇 |
1993年 | 29篇 |
1992年 | 43篇 |
1991年 | 43篇 |
1990年 | 34篇 |
1989年 | 27篇 |
1988年 | 35篇 |
1987年 | 23篇 |
1986年 | 33篇 |
1985年 | 23篇 |
1984年 | 23篇 |
1983年 | 20篇 |
1982年 | 10篇 |
1981年 | 9篇 |
1980年 | 11篇 |
1977年 | 15篇 |
1976年 | 13篇 |
1975年 | 9篇 |
1974年 | 9篇 |
1970年 | 10篇 |
1969年 | 13篇 |
排序方式: 共有4734条查询结果,搜索用时 15 毫秒
71.
The first recorded case of lymphoma of the bladder was reported by Eve and Chaffey in 1885. Malignant lymphoma of the bladder can be classified into one of three different clinical groups: 1) Primary lymphoma localized to the bladder; 2) Lymphoma presenting in the bladder as the first sign of disseminated disease (non-localized lymphoma); 3) Recurrent bladder involvement by lymphoma in patients with a history of malignant lymphoma (secondary lymphoma). Primary extranodal marginal zone lymphoma of mucosa associated lymphoid tissue (MALT type) of the urinary bladder, first described by Kempton et al in 1990, is the most common primary bladder lymphoma and associated with an excellent prognosis. We present a patient with gross hematuria who was found to have a primary bladder lymphoma and review the relevant literature. 相似文献
72.
Mahmoud?A.?Elshenawy M.?Shahzad Rauf Tusneem?A.M.?Elhassan Irfan?Maghfoor Saad?AkhtarEmail authorView authors OrcID profile 《Annals of hematology》2018,97(7):1229-1240
Hodgkin lymphoma (HL) patients failing after high dose chemotherapy (HDC) and auto-SCT have a poor outcome. Some patients may still benefit from further treatments. From 1996 to 2016, 137 HL patients (39.5%) out of 347 transplanted experienced post auto-SCT failure. Males/female 61%:39%, median age at auto-SCT 23.4 years and median follow-up 55.6 months (9–153). Type of failure was progressive (46%), relapsed (35%) or persistent disease/refractory disease (19%). Median overall survival (OS) from the time of failure is 20 months; 35 patients (25.5%) are alive. One hundred and four patients received treatment; the response rate was 45%; complete remission in 41 (30%) and partial remission in 21 (15%) patients. 1st interventions post auto-SCT were chemotherapy (39%), radiation therapy (35%) or best supportive care (24%). Twenty-seven patients with 2nd-SCT (allogeneic (15), auto-SCT (2)) and/or brentuximab (18 patients) had superior OS (50.6 months) vs other treatments (22.5 months, P value 0.037). COX regression multivariate analysis identified post auto-SCT treatment failure before 12 months (hazard ratio (HR) 3.37, CI 1.7–6.6, P value <?0.001), presence of B symptoms (HR 2.55, CI 1.4–4.6, P value 0.002), stages III–IV (HR 2.7, CI 1.5–4.9, P value 0.001), albumin <?4 g/dl (HR 1.76, CI 1.1–2.9, P value 0.027) and tumor >?5 cm (HR 1.1.9, CI 1.13–3.25, P value 0.015) as significant risk factors; P value <?0.001. KM OS with 0–1 factor (148.6 months): 2 factors (23.6 months) and 3–5 factors (9.4 months) (P value <?0.001). OS was 63%:25%:7% respectively with 0–1:2:3–5 factors respectively (P value <?0.001). Despite high-risk factors, 2nd-SCT/brentuximab use post HDC auto-SCT failure may result in durable survival. 相似文献
73.
Bogdan Moldoveanu Alessandra Morello Gearhart Bilal A. Jalil Mohamed Saad Juan J. Guardiola 《The American journal of the medical sciences》2021,361(4):411-419
Aspergillus species are ubiquitous in the environment. Aspergillosis is acquired by inhalation of Aspergillus spores. In normal hosts, spore inhalation rarely causes lung disease. Pulmonary Aspergillosis covers a wide spectrum of clinical syndromes depending on the interaction between Aspergillus and the host (immune-status, prior bronchopulmonary disease). It runs the gamut from invasive Aspergillosis to Aspergillus bronchitis. Invasive Aspergillosis usually occurs in severely immunocompromised patients, typically in neutropenic but also in non-neutropenic patients. Chronic pulmonary Aspergillosis affects patients with chronic structural lung disease such as COPD or previous mycobacterial lung disease, but without other significant immunocompromise. Aspergillus bronchitis affects patients with bronchial disease such as bronchiectasis. Allergic bronchopulmonary Aspergillosis affects patients with bronchial asthma or cystic fibrosis, and is due to an allergic response to Aspergillus. 相似文献
74.
75.
76.
Regulation of Cbl-associated protein/Cbl pathway in muscle and adipose tissues of two animal models of insulin resistance 总被引:2,自引:0,他引:2
The phosphatidylinositol 3-kinase-independent pathway to induce glucose transport may involve the tyrosine phosphorylation of the protooncogene c-Cbl. In the present study, we examined whether acute exposure to insulin stimulates the tyrosine phosphorylation of Cbl and its association with Cbl-associated protein (CAP) in muscle and adipose tissue of rats in vivo. We report herein that insulin induces Cbl tyrosine phosphorylation and association with CAP in adipose tissue but not in muscle. We also examined the expression and tyrosyl-phosphorylation state of Cbl and CAP/Cbl association in adipose tissue of rats submitted to prolonged fasting and in monosodium glutamate (MSG)-insulin-resistant rats. An increase in Cbl phosphorylation is observed in the fat of MSG rats, parallel with an increase in association of CAP-Cbl as well as an augment in CAP and Cbl protein expression in the adipose tissue of these animals. These events are accompanied by a decrease in insulin-stimulated insulin receptor/ insulin receptor substrate (IRS)-1 tyrosine phosphorylation and an increase in the IRS-2/phosphatidylinositol 3-kinase/Akt/Foxo1 pathway. In adipocytes of fasted rats, there is a decrease in CAP and Cbl protein expression, insulin-induced Cbl phosphorylation, and the association with CAP. In parallel, there is also a decrease in the insulin receptor/IRSs/Akt/Foxo1 pathway. Thus, insulin is able to induce Cbl tyrosine phosphorylation and its association with CAP in the adipose tissue of normal rats. In addition, our data provide evidence that the CAP-Cbl pathway may have a role in the modulation of adiposity in fasting and in MSG-treated rats. 相似文献
77.
78.
Sustained, retransplantable, multilineage engraftment of highly purified adult human bone marrow stem cells in vivo 总被引:4,自引:8,他引:4
Civin CI; Almeida-Porada G; Lee MJ; Olweus J; Terstappen LW; Zanjani ED 《Blood》1996,88(11):4102-4109
Data from many laboratory and clinical investigations indicate that CD34+ cells comprise approximately 1% of human bone marrow (BM) mononuclear cells, including the progenitor cells of all the lymphohematopoietic lineages and lymphohematopoietic stem cells (stem cells). Because stem cells are an important but rare cell type in the CD34+ cell population, investigators have subdivided the CD34+ cell population to further enrich stem cells. The CD34+/CD38- cell subset comprises less than 10% of human CD34+ adult BM cells (equivalent to < 0.1% of marrow mononuclear cells), lacks lineage (lin) antigens, contains cells with in vitro replating capacity, and is predicted to be highly enriched for stem cells. The present investigation tested whether the CD34+/CD38- subset of adult human marrow generates human hematopoiesis after transfer to preimmune fetal sheep. CD34+/ CD38- cells purified from marrow using immunomagnetic microspheres or fluorescence-activated cell sorting generated easily detectable, long- term, multilineage human hematopoiesis in the human-fetal sheep in vivo model. In contrast, transfer of CD34+/CD38+ cells to preimmune fetal sheep generated only short-term human hematopoiesis, possibly suggesting that the CD34+/CD38+ cell population contains relatively early multipotent hematopoletic progenitor cells, but not stem cells. This work extends the prior in vitro evidence that the earliest cells in fetal and adult human marrow lack CD38 expression. In summary, the CD34+/ CD38- cell population has a high capacity for long-term multilineage hematopoietic engraftment, suggesting the presence of stem cells in this minor adult human marrow cell subset. 相似文献
79.
Bruno?Fran?ois Emmanuelle?Mercier Céline?Gonzalez Karim?Asehnoune Saad?Nseir Maud?Fiancette Arnaud?Desachy Ga?tan?Plantefève Ferhat?Meziani Paul-André?de?Lame Pierre-Fran?ois?Laterre for the MASTER? study group 《Intensive care medicine》2018,44(11):1787-1796
Purpose
Hospital-acquired bacterial pneumonia (HABP) is a critical concern in hospitals with ventilator-associated bacterial pneumonia (VABP) remaining the most common infection in the ICU, often due to Staphylococcus aureus, an increasingly difficult to treat pathogen. Anti-infective monoclonal antibodies (mAb) may provide new, promising treatment options. This randomized, double-blinded, placebo-controlled study aimed at assessing the safety and pharmacokinetics of AR-301, an S. aureus alpha toxin-neutralizing mAb, and exploring its clinical and microbiologic outcomes when used adjunctively with standard-of-care antibiotics.Methods
Eligibility in this trial required microbiologically confirmed severe S. aureus pneumonia, including HABP, VABP or CABP, treated in the ICU and an APACHE II score ≤?30. Standard-of-care antibiotics selected by the investigators were administered to all patients in the study following clinical and microbiologic confirmation of S. aureus pneumonia. Adjunctive treatment of AR-301 was to start <?36 h after onset of severe pneumonia. AR-301 was administered to four sequentially ascending dose cohorts. The placebo cohort received antibiotics and a placebo buffer. Clinical outcomes were adjudicated by a blinded committee. S. aureus eradication was declared based on a negative follow-up culture and presumed to be negative when no culture was obtained in the presence of clinical improvement.Results
Thirteen ICUs enrolled 48 patients, with pneumonia attributable to MRSA in six subjects. The study drug displayed a favorable safety profile: Of 343 AEs reported, 8 (2.3%) were deemed related, none serious. In a post hoc subgroup analysis of VABP patients receiving AR-301, ventilation duration was shorter for AR-301-treated patients compared with the placebo group. Overall, there was a trend toward a better and faster microbiologic eradication at day 28. The PK profile of AR-301 is consistent with that of a human IgG1 mAb, with a plasma half-life of about 25 days.Conclusions
Adjunctive treatment of severe S. aureus HABP with anti-staphylococcal mAbs appears feasible and suggests some clinical benefits, but larger randomized studies are needed to better define its safety and efficacy.80.
Kamal Medlej Amin Antoine Kazzi Ahel El Hajj Chehade Mothana Saad Eldine Ali Chami Rana Bachir Dina Zebian Gilbert Abou Dagher 《The Journal of emergency medicine》2018,54(1):47-53